Medicus Pharma Ltd. Common Stock (MDCX) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
211.90
↓-41% vs avg
5yr avg: 358.06
30Y Low7.5·High7.5
ROE
↓
-1599.4%
↑-84% vs avg
5yr avg: -867.7%
30Y Low-478%·High-478%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MDCX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Medicus Pharma Ltd. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $10M | $26M | $23M | — | — | — |
| Enterprise Value | $5M | $22M | $20M | — | — | — |
| P/E Ratio → | -0.23 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 211.90 | 708.66 | 7.46 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MDCX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
MDCX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -1599.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -1599.4% | -1599.4% | -525.4% | -478.2% | — | — |
| ROA | -323.0% | -323.0% | -295.9% | -488.6% | -937.2% | -2617.7% |
| ROIC | — | — | — | — | — | — |
| ROCE | -1059.5% | -1059.5% | -502.3% | -425.6% | — | — |
MDCX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 107.09 | 107.09 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -126.23 | -1.23 | -1.55 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -129.91 | -129.91 | -35.13 | -4.46 | -2.21 | -16.81 |
Net cash position: cash ($9M) exceeds total debt ($4M)
MDCX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 1.00x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.42x to 1.00x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.00 | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 |
| Quick Ratio | 1.00 | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 |
| Cash Ratio | 0.88 | 0.88 | 1.81 | 2.20 | 0.02 | 0.01 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
MDCX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Medicus Pharma Ltd. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $17M | $10M | $5M | $8M | $8M |
Peer Comparison
Compare MDCX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MDCXYou | $10M | -0.2 | — | — | — | — | -1599.4% | — | — |
 SIGA | $310M | 13.1 | 6.4 | 7.2 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 NUVB | $2B | -9.3 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 TPVG | $203M | 4.1 | 8.6 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 DERM | $171M | -13.2 | — | — | 59.3% | -13.2% | -44.0% | -36.8% | — |
 NTRB | $36M | -1.1 | — | — | 25.7% | -408.4% | -125.6% | -268.1% | — |
 SKIN | $86M | -4.1 | 51.0 | 2.3 | 65.3% | -6.9% | -16.9% | -6.8% | 83.3 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -63.6 | 12.9 | 17.2 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 ICLR | $11B | 50.3 | 10.1 | 13.0 | 26.4% | 12.3% | 2.5% | 6.2% | 2.5 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MDCX — Frequently Asked Questions
Quick answers to the most common questions about buying MDCX stock.
What is Medicus Pharma Ltd. Common Stock's P/E ratio?
Medicus Pharma Ltd. Common Stock's current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Medicus Pharma Ltd. Common Stock's ROE?
Medicus Pharma Ltd. Common Stock's return on equity (ROE) is -1599.4%. The historical average is -478.2%.
Is MDCX stock overvalued?
Based on historical data, Medicus Pharma Ltd. Common Stock is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.